Leukemia and Lymphoma

Drug Combination Used in Adults Can Benefit Children With Acute Promyelocytic Leukemia

November 24th 2021, 9:01pm


All-trans retinoic acid and arsenic trioxide used together can let children avoid treatment with convention chemotherapy, which has more adverse effects.

Hospitals Lack Medication Needed for Form of AML, Study Finds

November 20th 2021, 12:40pm


Although acute promyelocytic leukemia is highly treatable in early stages, the medication needed stop hematologic emergencies, all-trans retinoic acid, is often not available, a new study says.

HRQOL Decreased During and Immediately After CAR T-Cell Therapy for DLBCL

November 16th 2021, 8:45pm


Prior to chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), patients experienced a decrease in health-related quality of life (HRQOL), which was further impaired during and immediately after CAR T therapy.

Safety Analysis Finds Zanubrutinib’s Toxicity Profile Is Consistent With Other BTK Inhibitors

November 13th 2021, 3:30pm


A safety analysis of 6 trials found zanubrutinib has a toxicity profile consistent wth other Bruton tyrosine kinase (BTK) inhibitors.

Researchers Report Further Analysis of Zanubrutinib Monotherapy for R/R MCL

November 13th 2021, 11:45am


Fewer Blood Transfusions for Patients With AML Has Humanistic, Economic Benefits

November 5th 2021, 7:15pm


Posters presented at the Academy of Managed Care Pharmacy Nexus 2021 meeting analyzed patient and physician perspectives on blood transfusions in acute myeloid leukemia (AML).

Tazemetostat Yields Fewer Safety Outcomes, Lower AE-Associated Costs vs PI3 Kinase Inhibitors

November 3rd 2021, 4:07pm


Two analyses presented at the Academy of Managed Care Pharmacy Nexus 2021 meeting highlighted the safety and cost benefits of tazemetostat compared with phosphoinositide 3 (PI3) kinase inhibitors for patients with follicular lymphoma.

The Cost of Treating AEs Due to CAR T-Cell Therapy Treatment

October 30th 2021, 7:30pm


Two posters presented at AMCP Nexus 2021 analyzed the costs of treating cytokine release syndrome and neurological events, 2 common adverse events (AEs) of chimeric antigen receptor (CAR) T-cell therapy.

Comparing Costs and HRU for Tisagenlecleucel vs Axicabtagene Ciloleucel for DLBCL

October 25th 2021, 8:30pm


Posters presented at AMCP Nexus 2021 evaluated the health care resource utilization (HRU) and costs associated with the chimeric antigen receptor T-cell therapies tisagenlecleucel and axicabtagene ciloleucel.

Zanubrutinib Cost-effective and Cost Saving vs Ibrutinib in Waldenström Macroglobulinemia

October 22nd 2021, 1:45pm


Posters presented at the AMCP Nexus 2021 meeting reviewed the cost-effectiveness and cost per response for zanubrutinib vs ibrutinib.